NCT01289054View on ClinicalTrials.gov

A Global Imatinib and Nilotinib Pregnancy Exposure Registry

CompletedOBSERVATIONAL
Enrollment

4

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
All Indications for Glivec/Gleevec and Tasigna
Interventions
DRUG

Tasigna

DRUG

Gleevec

Trial Locations (1)

28405

INC Research, LLC, Wilmington

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY